NeuroSense Advances ALS Therapy PrimeC Toward Canadian Filing
NeuroSense provided a business update and first-half 2026 results, saying it is advancing PrimeC as a potential treatment for ALS. The company is targeting a December 2026 New Drug Submission in Canada and is pursuing a capital-efficient U.S. development path that may include an active-comparator study against edaravone. It also plans to discuss with the FDA whether existing data could support full approval or an accelerated pathway.
NeuroSense completed Health Canada pre-submission steps and aims to file a New Drug Submission for PrimeC in ALS by December 2026; Health Canada saw no timeline concerns and aligned on submission structure. In the U.S., it is considering an edaravone comparator trial, a smaller, shorter PARAGON pivotal design, AI-based formulation work, and FDA talks on full or accelerated approval.
Phase 2b PARADIGM results were published in JAMA Neurology. Long-term follow-up found a 65% lower death risk and median survival of 36.3 months with continuous PrimeC versus 21.4 months for those initially on placebo before crossover. The study met its primary endpoint by reducing extracellular vesicle-associated TDP-43, present in more than 97% of ALS cases.
If PrimeC advances, people living with ALS and their caregivers could gain another potential treatment option, though access would depend on regulatory decisions, evidence strength, pricing, and coverage. Clinicians may get additional biomarker and survival data to weigh alongside existing therapies. The case may also influence how regulators and developers approach smaller trials, active comparators, and accelerated pathways for neurodegenerative diseases. Investors and patient groups could watch Canada's filing and FDA discussions as signals for the program's viability.